Home > Mycotherapy: potential of fungal bioactives for the treatment of mental health disorders and morbidities of chronic pain.

Meade, Elaine and Hehir, Sarah and Rowan, Neil and Garvey, Mary (2022) Mycotherapy: potential of fungal bioactives for the treatment of mental health disorders and morbidities of chronic pain. Journal of Fungi, 8, (3), 290. doi: 10.3390/jof8030290.

External website: https://www.mdpi.com/2309-608X/8/3/290

Mushrooms have been used as traditional medicine for millennia, fungi are the main natural source of psychedelic compounds. There is now increasing interest in using fungal active compounds such as psychedelics for alleviating symptoms of mental health disorders including major depressive disorder, anxiety, and addiction. The anxiolytic, antidepressant and anti-addictive effect of these compounds has raised awareness stimulating neuropharmacological investigations. Micro-dosing or acute dosing with psychedelics including Lysergic acid diethylamide (LSD) and psilocybin may offer patients treatment options which are unmet by current therapeutic options. Studies suggest that either dosing regimen produces a rapid and long-lasting effect on the patient post administration with a good safety profile. Psychedelics can also modulate immune systems including pro-inflammatory cytokines suggesting a potential in the treatment of auto-immune and other chronic pain conditions. This literature review aims to explore recent evidence relating to the application of fungal bioactives in treating chronic mental health and chronic pain morbidities.


Item Type
Article
Publication Type
International, Open Access, Review, Article
Drug Type
CNS stimulants, New psychoactive substance
Intervention Type
Drug therapy, Treatment method
Date
11 March 2022
Identification #
doi: 10.3390/jof8030290
Volume
8
Number
3
EndNote

Repository Staff Only: item control page